The National Institute for Health and Care Excellence (NICE) has issued a positive Final Appraisal Document recommending Leo Pharma’s Adtralza (tralokinumab), Rinvoq (upadacitinib) and Cibinqo (abrocitinib) for use within NHS England and Wales.
The therapy is for moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic treatment, if the disease has not responded to at least one systemic immunosuppressant or if that initial treatment was unsuitable…
